Rockefeller Capital Management L.P. Acquires 215,283 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Rockefeller Capital Management L.P. boosted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 323.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 281,922 shares of the company's stock after purchasing an additional 215,283 shares during the period. Rockefeller Capital Management L.P. owned about 0.07% of Recursion Pharmaceuticals worth $1,906,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Decker Retirement Planning Inc. bought a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $26,000. Private Trust Co. NA bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $27,000. GAMMA Investing LLC grew its stake in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after acquiring an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC raised its stake in Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in Recursion Pharmaceuticals by 220.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock valued at $66,000 after purchasing an additional 6,758 shares during the period. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Trading Up 1.9 %

RXRX traded up $0.11 during midday trading on Thursday, hitting $5.69. 5,081,225 shares of the company were exchanged, compared to its average volume of 23,577,066. The firm has a market capitalization of $2.29 billion, a P/E ratio of -3.72 and a beta of 1.00. The firm's 50 day moving average price is $6.40 and its 200-day moving average price is $6.78. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business's revenue for the quarter was down 57.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.42) EPS. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. KeyCorp cut their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Needham & Company LLC restated a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Morgan Stanley dropped their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Finally, Leerink Partners lowered their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of "Hold" and an average target price of $8.20.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.